Sign in

    Teresa Vitale

    Research Analyst at Scotiabank

    Teresa Vitale is an Analyst at Scotiabank, focusing on biotechnology sector research with coverage that includes companies such as Geron Corp. While detailed third-party metrics and historical rankings are limited, her recent track record includes direct participation in earnings calls and analysis for major biopharmaceutical firms. Vitale began her research career at Scotiabank and has contributed specialized insight into biotech equities, supporting institutional clients with tailored research coverage. Her professional profile also suggests familiarity with regulatory practices and investment analysis typical for industry analysts at major sell-side firms.

    Teresa Vitale's questions to GERON (GERN) leadership

    Teresa Vitale's questions to GERON (GERN) leadership • Q1 2025

    Question

    Teresa Vitale of Scotiabank inquired about commercial strategies to encourage physicians to switch patients from luspatercept to RYTELO sooner, and asked about the reasons for any KOL hesitation to prescribe RYTELO in earlier lines of therapy.

    Answer

    Jim Ziegler, Chief Commercial Officer, noted that market research shows physician awareness of RYTELO's profile drives favorable perceptions and that recent data shows 20% of use is now in first and second lines. Dr. Joseph Eid, EVP of R&D, added that data presented at ASH demonstrated imetelstat's efficacy post-luspatercept and that physician hesitancy often stems from a lack of awareness, which is overcome with education on the drug's unique mechanism.

    Ask Fintool Equity Research AI